They showed that treatment with AREG upregulates sprouty RTK signaling antagonist 2 (SPRY2) expression by activating the EGFR-mediated ERK1/2 signaling pathway in ovarian cancer [66]. This evidence concerns the gene SPRY2 and ovarian carcinoma.